STL Index for: Taylor Evart Woo

A review of the long-term efficacy and safety of tildrakizumab, a monoclonal antibody targeting the IL-23/IL-17 pathway, in treating moderate-to-severe plaque psoriasis. Evidence from Phase 3 clinical trials and extension studies demonstrates that tildrakizumab is an effective and well-tolerated therapy, significantly improving skin clearance and maintaining a favorable safety profile over several years of use.

Dupilumab: A groundbreaking FDA and Health Canada-approved treatment for Prurigo Nodularis (PN). This innovative therapy targets IL-4 and IL-13 signalling, effectively reducing inflammation, pruritus, and lesions. Its approval marks a paradigm shift in PN management, offering new hope for patients.

Clascoterone 1% cream represents a novel and promising therapeutic agent in the management of acne vulgaris for individuals ≥12 years of age. Notably, this topical agent was not observed to have significant systemic effects seen with systemic anti-androgenic agents.

Crisaborole represents a novel and efficacious therapeutic approach for the treatment of mild to moderate Atopic Dermatitis and demonstrates early and continued decrease in pruritus, which improves quality of life and reduces the potential risk of infection and scarring.